Which factors influence psychiatrists' selection of antidepressants?

American Journal of Psychiatry

Volumn 161, Issue 7, 2004, Pages 1285-1289

  Zimmerman, Mark ^a,b   Posternak, Michael ^a   Friedman, Michael ^a   Attiullah, Naureen ^a   Baymiller, Scott ^a   Boland, Robert ^a   Berlowitz, Stacie ^a   Rahman, Shahzad ^a   Uy, Kirsten ^a   Singer, Steve ^a  

^a BROWN UNIVERSITY   (United States)

^b Bayside Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PAROXETINE; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; AGITATION; ANAMNESIS; ANTICHOLINERGIC EFFECT; ANXIETY; ARTICLE; CLINICAL RESEARCH; COMORBIDITY; DEPRESSION; EVIDENCE BASED MEDICINE; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; MENTAL PATIENT; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHIATRIST; QUESTIONNAIRE; SEXUAL DYSFUNCTION; SIDE EFFECT; SYMPTOM; TREATMENT FAILURE; WEIGHT GAIN; WITHDRAWAL SYNDROME;

ANTIDEPRESSIVE AGENTS; CHOICE BEHAVIOR; DEPRESSIVE DISORDER; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; PSYCHIATRY; QUESTIONNAIRES; RESEARCH; TREATMENT OUTCOME;

EID: 3042820380     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.161.7.1285     Document Type: Article

References (19)

1. Nemeroff CB: Recent advances in the neurobiology of depression. Psychopharmacol Bull 2002; 36:6-23
2. Nutt D: Substance-P antagonists: a new treatment for depression? Lancet 1998; 352:1644-1646
3. Krishnan KRR: Clinical experience with substance P receptor (NK1) antagonists in depression. J Clin Psychiatry 2002; 63(suppl):25-29
4. American Psychiatric Association: Practice Guideline for the Treatment of Patients With Major Depressive Disorder (Revision). Am J Psychiatry 2000; 157(April suppl)
5. Benazzi F: Psychomotor changes in melancholic and atypical depression: unipolar and bipolar-II subtypes. Psychiatry Res 2002; 112:211-220
6. Melartin TK, Rytsala HJ, Leskela US, Lestela-Mielonen PS, Sokero TP, Isometsa ET: Current comorbidity of psychiatric disorders among DSM-IV major depressive disorder patients in psychiatric care in the Vantaa Depression Study. J Clin Psychiatry 2002; 63:126-134
7. Zimmerman M, Chelminski I, McDermut W: Major depressive disorder and axis I diagnostic comorbidity. J Clin Psychiatry 2002; 63:187-193
8. Petersen T, Dording C, Neault N, Kornbluh R, Alpert J, Nierenberg A, Rosenbaum J, Fava M: A survey of prescribing practices in the treatment of depression. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26:177-187
9. Olfson M, Marcus SC, Druss B, Elinson L, Tanielian T, Pincus HA: National trends in the outpatient treatment of depression. JAMA 2002; 287:203-209
10. Olfson M, Marcus SC, Pincus HA, Zito JM, Thompson JW, Zarin DA: Antidepressant prescribing practices of outpatient psychiatrists. Arch Gen Psychiatry 1998; 55:310-316
11. Pincus HA, Tanielian TL, Marcus SC, Olfson M, Zarin DA, Thompson J, Zito JM: Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties. JAMA 1998; 279:526-531
12. Zimmerman M, Posternak MA, Attiullah N, Baymiller SF, Berlowitz SL, Boland RJ, Friedman M: Factors associated with anti-depressant choice survey: choosing among SSRIs, in 2002 Annual Meeting New Research Program and Abstracts. Washington, DC, American Psychiatric Association, 2002, number 237
13. Fawcett J: The detection and consequences of anxiety in clinical depression. J Clin Psychiatry 1997; 58(suppl 8):35-40
14. Posternak MA, Zimmerman M, Keitner GI, Miller IW: A reevaluation of the exclusion criteria used in antidepressant efficacy trials. Am J Psychiatry 2002; 159:191-200
15. Rush AJ, Batey SR, Donahue R, Ascher JA, Carmody TJ, Metz A: Does pretreatment anxiety predict response to either bupropion SR or sertraline? J Affect Disord 2001; 64:81-87
16. Rush JA, Trivedi MH, Carmody TJ, Donahue R, Houser BA, Bolden-Watson C, Batey SR, Pharm D, Ascher JA, Metz A: Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. Neuropsychopharmacology 2001; 25:131-138
17. Zimmerman M, Spitzer RL: Melancholia: from DSM-III to DSM-III-R. Am J Psychiatry 1989; 146:20-28
18. Posternak M, Zimmerman M: The validity of atypical depression. Arch Gen Psychiatry 2002; 59:70-76
19. Zimmerman M, Mattia JI, Posternak MA: Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry 2002; 159: 469-473